Welcome to our dedicated page for Prothena news (Ticker: PRTA), a resource for investors and traders seeking the latest updates and insights on Prothena stock.
Prothena Corporation plc develops investigational therapeutics built on protein dysregulation expertise for neurodegenerative and rare peripheral amyloid diseases. Company news commonly covers clinical and partner updates for programs such as prasinezumab in Parkinson’s disease, coramitug in ATTR amyloidosis with cardiomyopathy, BMS-986446 in Alzheimer’s disease, PRX019, and CYTOPE-based research.
Updates also include financial results, cash guidance, collaboration revenue and milestone payments from strategic partners, regulatory designations, share repurchase activity, shareholder capital actions, and leadership or governance changes.
Prothena Corporation (NASDAQ:PRTA) reported a net loss of $26.3 million for Q2 2020, significantly higher than $15.8 million in Q2 2019. Total revenue for Q2 remained stable at $0.2 million. The company’s cash position is strong, with $336.6 million available to fund ongoing R&D efforts. Upcoming milestones include presentations of clinical data for their Parkinson’s disease treatment, prasinezumab, and updates on PRX004 for ATTR amyloidosis. Prothena expects full-year cash burn between $75-$85 million, predicting an end-of-year cash position of approximately $299 million.
Prothena Corporation (NASDAQ: PRTA) announced that results from Part 1 of the Phase 2 PASADENA study on prasinezumab for early Parkinson’s disease were selected as an oral Top Abstract at the International Congress of Parkinson’s Disease and Movement Disorders Society (MDS). This session will take place on September 14, 2020, with a poster also displayed in the virtual hall. Prasinezumab aims to block the transmission of aggregated alpha-synuclein, potentially slowing disease progression. Prothena continues its collaboration with Roche, focusing on achieving significant milestones.
Prothena Corporation plc (NASDAQ: PRTA) will announce its Q2 and H1 2020 financial results on August 6, after U.S. market close. The company specializes in neurodegenerative and rare peripheral amyloid diseases, with a pipeline of investigational therapeutics. Notably, Prothena collaborates with Roche on prasinezumab for Parkinson’s disease and partners with Bristol-Myers Squibb on therapies targeting Alzheimer’s and other diseases. Consistent with previous practices, there will be no conference call following the earnings release.
DUBLIN, Ireland, May 27, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA) announced its senior management will present at the Jefferies Virtual Healthcare Conference on June 3 at 3:30 PM ET. Investors can access the presentation via the investor relations section of the company's website. A replay will be available for 90 days post-presentation. Prothena focuses on the discovery of therapies for diseases related to protein misfolding, including Alzheimer's and Parkinson's, with a diverse pipeline of partnered and proprietary programs.
Prothena Corporation reported a net loss of $23.6 million for Q1 2020, compared to $20.9 million in Q1 2019, with a net loss per share of $0.59. Total revenue from its collaboration with Roche was only $0.1 million, down from $0.2 million. R&D expenses rose to $15.2 million due to collaboration costs and clinical trials. The cash position remains strong at $355.4 million, but the net cash burn for 2020 is estimated at $75 to $85 million, up from previous guidance. Prothena has ongoing evaluations for its drug programs, including prasinezumab.